Clinical Trials

    A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma

    Investigator: Siddhartha Ganguly

    Study Coordinator: Pauline Ngban

    Status: Open Not Enrolling

    ClinicalTrials.gov Number: NCT06208150

    Phone: 346.260.9908

    Protocol Number: PRO00038188

    Description


    The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone (PVd).